Next generation complement therapeutics market is anticipated to rise by 6% rate in the coming decade, predicts Roots Analysis
Dysregulation in complement system may result in several common to rare disorders; therapeutics targeting the complement system have demonstrated significant potential to effectively treat these disorders
Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Complement Therapeutics Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain. Amongst other elements, the report includes:
- A detailed review of the current market landscape of next generation complement therapeutics along with their developers.
- Presently, 190+ complement therapeutics have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
- Close to 80% of the pipeline candidates are under clinical evaluation. Further, therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO®, have been approved for the treatment of Hereditary Angioedema. Majority (84%) of these candidates are biologics, followed by small molecules (16%).
- Around 50 industry and non-industry players are engaged in the development of next generation complement therapy
- North America has emerged as the hub, featuring the presence of approximately 50% developers. The market is currently dominated by the presence of mid-sized players (37% of the total number of stakeholders). Interestingly, 15% of the players are big pharma companies engaged in the development of such therapeutics for multiple therapeutic areas.
- Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size).
- An in-depth analysis of more than 850 completed, ongoing and planned clinical studies of various next generation complement therapeutics.
- A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, published during 2017-2021.
- An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021.
- An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021.
- An analysis of the partnerships that have been established in this domain since 2014.
- A detailed analysis of the various funding and investments made since 2014, in the companies focused on the development of next generation complement therapeutics.
- An analysis of big pharma players engaged in the field of next generation complement therapeutics.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
- Target Disease Indication
- Atypical Hemolytic Uremic Syndrome
- Cardiac Transplantation Rejection
- Cold Agglutinin Disease
- COVID-19
- Generalized Myasthenia Gravis
- Guillain-Barre Syndrome
- Hereditary Angioedema
- Neuromyelitis Optica
- Paroxysmal Nocturnal Hemoglobinuria
- Therapeutic Area
- Cardiovascular Disorders
- Genetic Disorders
- Hematological and Vascular Disorders
- Infectious Diseases
- Neurological Disorders
- Neuromuscular Disorders
- Type of Molecule
- Biologic
- Small Molecule
- Target Pathway
- Alternate Pathway
- Classical Pathway
- Lectin Pathway
- Terminal Pathway
- Type of Therapy
- Monotherapy
- Combination Therapy
- Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
Key companies covered in the report
- Amgen
- CSL Behring
- Innovent Biologics
- Novartis
- Regeneron
- Roche
- Sanofi
- Takeda
- UCB
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html
or email sales@rootsanalysis.com
Other Recent Offerings:
- Gene Editing beyond CRISPR Market, 2022-2035
- Myeloid Cells Targeting Therapeutics Market, 2021-2035
- Thermostable Vaccines and Thermostable Biologics Market, 2021-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
Quora – https://rootsanalysisinsights.quora.com/
